隶属于 the johns hopkins health system corp.
相关临床试验
0
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
暂无试验阶段数据
暂无试验数据
暂无试验数据
暂无批准数据
- A 69-year-old woman's persistent abdominal bloating was ultimately diagnosed as Stage 4 ovarian cancer after a nurse practitioner ordered a CT scan instead of the expected colonoscopy. - Oncologist Dr. Premal Thaker of Washington University School of Medicine describes ovarian cancer as "very insidious," with subtle symptoms that mimic menopause or milder conditions. - Patients with Stage 4 ovarian cancer have roughly a 30% five-year survival chance, and about 70% of patients will see their disease return, according to cited organizations. - The patient's treatment combined neoadjuvant chemotherapy, February 2025 surgery including hysterectomy, resumed chemotherapy, immunotherapy infusions, and an ongoing daily chemotherapy pill.
- Lung cancer remains the leading cause of cancer death in the United States, with only 27% of cases caught early. - Biomarker testing, including PD-L1 and mutation testing, helps oncologists determine the most precise and effective treatment plans for lung cancer patients. - Dr. Julie Brahmer of Johns Hopkins explains that PD-L1 acts as an "invisibility cloak" for cancer cells, and drugs blocking this protein allow the immune system to recognize and attack tumors. - Patients are urged to ask their physicians about staging, cancer type, and comprehensive biomarker testing results to ensure optimal treatment from the outset.
- Protaryx Medical received FDA 510(k) clearance for its proprietary transseptal puncture device designed to facilitate safe left-heart access for cardiac interventions. - The device features zero-exchange delivery with an extendable positioning probe and radiofrequency guidewire technology compatible with standard electrosurgical generators. - Early clinical evaluation in a first-in-human study of five patients demonstrated 100% procedural success with no device-related adverse events. - The technology aims to simplify transseptal access procedures for treatments including atrial fibrillation ablation, left atrial appendage closure, and mitral valve repair.
- A first-of-its-kind meta-analysis of 574 men with oligometastatic prostate cancer demonstrates that metastasis-directed therapy significantly improves progression-free survival by 7.6 months compared to standard care alone. - The WOLVERINE study, published in The Lancet Oncology, provides the highest level of evidence to date supporting metastasis-directed therapy, primarily stereotactic body radiation therapy, for treating limited metastatic disease. - Patients receiving metastasis-directed therapy showed consistent benefits across multiple endpoints including radiographic progression-free survival and castration resistance-free survival, with no additional safety risks observed.
- CraniUS Therapeutics raised $20 million in Series B financing to accelerate development of NeuroPASS™, a fully implantable skull-embedded platform designed to bypass the blood-brain barrier for targeted drug delivery. - The neurotechnology company was founded by Dr. Chad Gordon, a Johns Hopkins neuroplastic surgeon, to address the clinical challenge that life-saving therapies often cannot reach the brain due to the blood-brain barrier. - The funding will support operations into 2027 and enable regulatory submissions, manufacturing scale-up, and product testing towards future commercialization of the multi-product platform. - CraniUS appointed Johnson & Johnson veteran Oray Boston Jr. to its board of directors, bringing over 35 years of global healthcare leadership experience to guide commercialization strategies.
- A clinical trial found that next-day HIV viral load test results did not significantly boost care-seeking for antiretroviral therapy or prevention measures. - Researchers identified that the median turnaround time of more than 24 hours prevented same-day treatment initiation, potentially missing critical opportunities for rapid linkage to care. - Lead investigator Matthew Hamill suggests future trials should explore immediate viral load feedback and same-day treatment initiation to improve HIV treatment and prevention outcomes. - The study concludes that more comprehensive interventions combining rapid testing with immediate therapy initiation may be necessary for effective HIV care.
- The Robert Packard Center for ALS Research at Johns Hopkins and ALS United have announced a collaborative funding partnership to support preclinical basic science research into amyotrophic lateral sclerosis. - The joint grant will fund research led by Albert La Spada, MD, PhD and Sandrine Da Cruz, PhD investigating alternative polyadenylation-driven RNA mislocalization in TDP-43 proteinopathies. - This partnership aims to accelerate breakthrough discoveries in ALS pathogenesis and identify novel therapeutic targets through strategic research collaboration. - The collaboration represents a model for future joint funding efforts in the ALS research community, combining resources to maximize scientific impact.
- Percheron Therapeutics has appointed Dr Eugene Kennedy as Chief Medical Officer and Valentina Dubljevic as Chief Technology Officer to strengthen leadership ahead of HMBD-002's phase II trial. - HMBD-002 is a monoclonal antibody targeting the immune checkpoint regulator VISTA that has completed phase I testing with favorable safety and tolerability data. - The company plans to commence recruitment for the phase II trial of HMBD-002 in calendar year 2026, marking a critical advancement in the oncology program. - Dr Kennedy brings over a decade of immuno-oncology experience from roles at Johns Hopkins and Carisma Therapeutics, while Dubljevic will focus on manufacturing and regulatory compliance.
- Johns Hopkins researchers developed a novel three-biomarker urine panel (TTC3, H4C5, and EPCAM) that detects prostate cancer with 91% sensitivity and 84% specificity. - The panel significantly outperformed existing urinary PCA3 RNA testing, achieving an area under the curve of 0.92 compared to 0.76 for PCA3 in validation studies. - The test successfully diagnosed prostate cancer in 86% of PSA-negative cases and distinguished cancer from benign conditions like prostatitis with 84-89% accuracy. - This noninvasive diagnostic approach could reduce unnecessary biopsies while improving early detection, particularly in patients with negative PSA results.
- Mosaic Neuroscience and iXCells Biotechnologies launched a groundbreaking pilot project to develop patient-specific models of sporadic ALS, which accounts for 90% of ALS cases. - The initiative aims to address the 99% failure rate of ALS treatments by creating "neurobiopsies" - lab-grown neurons that replicate individual patient disease patterns. - Project Mosaic adapts precision medicine methods from cancer research to transform ALS drug development, moving away from familial ALS models that represent fewer than 10% of patients. - The pilot will use patient-derived stem cell lines to generate transcriptomic signatures unique to each sporadic ALS patient, potentially enabling personalized drug matching.
